$1.600
+0.235 (+14.70%)At close
NRSN Comparative Benchmarking
In the context of the broader market, NRSN competes directly with industry leaders such as JAGX and LIMN. With a market capitalization of $3.04M, it holds a significant position in the sector. When comparing efficiency, NRSN's gross margin of N/A stands against JAGX's 15.84% and LIMN's N/A. Such benchmarking helps identify whether Neurosense Therapeutics Ltd is trading at a premium or discount relative to its financial performance.
Neurosense Therapeutics Ltd Financial Performance
Neurosense has reported consistent net losses, with a net income of -3.56 million in the first half of 2026, indicating ongoing financial struggles. The current ratio has dropped to 0.28, highlighting liquidity issues.
Financials
Related articles
- CPI Report and the Stock Market: How to Read October 2026 Inflation Data Before the Fed DecidesOctober 2026 CPI lands Nov 10 with no year-over-year number and Fed hike odds near 80%. Learn how to read CPI, which stocks react, and how to plan for it.
- Are You Buying NVIDIA’s Earnings or Its CEO’s Perfect Image?An Alphio analysis of NVIDIA’s share-price timeline, operating results, governance uncertainty and upcoming earnings.
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.